Comparative Pharmacology
Head-to-head clinical analysis: SULFACEL 15 versus SULFALOID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULFACEL 15 versus SULFALOID.
SULFACEL-15 vs SULFALOID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfacetamide inhibits bacterial dihydropteroate synthase, blocking para-aminobenzoic acid (PABA) incorporation into dihydrofolate, thereby inhibiting folate synthesis and bacterial growth.
Sulfaloid is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, blocking folate synthesis and thereby nucleic acid production in susceptible bacteria.
Adults: 15 mg/kg orally every 6 hours for 10 days; maximum single dose 1 g.
500 mg orally every 12 hours for 7-10 days.
None Documented
None Documented
Expected ~6-9 hours based on related sulfacetamide; however, no specific data for SULFACEL-15. Clinical context: prolonged in renal impairment.
Terminal elimination half-life: 6-8 hours in adults with normal renal function (ClCr >90 mL/min); prolonged to 12-20 hours in moderate renal impairment (ClCr 30-50 mL/min) and >30 hours in severe renal impairment (ClCr <30 mL/min).
Renal: ~85-90% unchanged; Biliary/Fecal: ~5-10% (metabolites and unchanged drug); ~5% eliminated via feces following biliary secretion.
Renal: 70% (unchanged via glomerular filtration and tubular secretion); Biliary/fecal: 20% (conjugated metabolites); 10% metabolized in liver to inactive acetylated derivatives.
Category C
Category C
Antibiotic (Sulfonamide)
Antibiotic (Sulfonamide)